Option chain shows key data for iBio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for iBio.

iBio (AMEX:IBIO) Stock, Option Chain

iBio

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Doctor,Measuring,Obese,Man,Waist,Body,Fat.,Obesity,And,Weight

Biotech

News

Health Care

Contracts

General

IBIO

iBio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous use, targeting reduced dosing frequency.

Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform

Come gli analisti valutano General Mills prima dei risultati del Q1

Earnings

Pre-Market Outlook

Markets

Trading Ideas

PIXY

RCAT

UXIN

AAR, ShiftPixy And 3 Stocks To Watch Heading Into Monday

Movers

iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity &amp; cardiometabolic conditions. Shares soared over 100%, hitting $2.44. Collaboration aims to target TGFb superfamily for muscle wasting &amp; obesity treatment.

Micro-Cap Stock iBio Doubles On Wednesday - Here&#39;s Why

iBio Inc

iBio To Begin Trading On Nasdaq On March 4, 2025 Under "IBIO"

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.32) by 50 percent. This is a 80.17 percent increase over losses of $(2.42) per share from the same period last year. The company reported $200.00 thousand in sales this quarter.

Earnings Misses

iBio Q2 EPS $(0.48) Misses $(0.32) Estimate, Sales $200.00K

iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.

iBio In Collaboration With AstralBio, Announced The Development Of An Antibody That Inhibits The Function Of Activin E, Therapeutic Target For Cardiometabolic Disorders And Obesity Using iBio's Machine-learning Antibody Engine

On Thursday, iBio, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc.
In March, iBio collaborated with&nbsp;AstralBio to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37959621/micro-cap-stock-ibio-doubles-on-wednesday-heres-why" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The antibody, now named IBIO-600, was identified by AstralBio using iBio&#8217;s proprietary technology stack. It was designed for subcutaneous administration and has the potential for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42761297/ibio-expands-cardiometabolic-and-obesity-program-with-anti-myostatin-antibody-discovered-using-its" rel="noreferrer noopener">an extended half-life</a>.
AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio.
In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million.
If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees.
iBio is solely responsible for the research and development, manufacturing, and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform and the technology of IBIO-600.
The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago.
iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.
In preclinical studies, IBIO-600 exhibits potent inhibition of myostatin in human muscle cell precursors, effectively blocking its inhibitory effects on muscle growth.
The company adds that IBIO-600 has been engineered to bind to the FcRn receptor with more than 10-fold higher affinity than normal IgG, supporting the potential for reduced dosing frequency.
The molecule has been advanced into non-cGMP&nbsp;in vivo studies in rodents and non-human primates, with the first data read-outs expected in early 2025.
iBio plans to use the machine-learning and epitope-steering capabilities of the Stable HU antibody optimizer with advanced mammalian display to design and produce additional multispecific antibodies targeting TGF-beta superfamily, including Myostatin and Activin A in in-vitro studies.
Price Action: At last check on Thursday, IBIO stock was up 2.04% at $2.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report">US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report</a></li>
</ul>
Photo via Shutterstock

<a href="https://www.globenewswire.com/Tracker?data=HZylVBKL9vtxA17iySuvrrc1wp4Rcx0tltN78FWTAZ1BeixIwg73Ye6eUEMmQfWgdAnz37k-BL0SwZd3n1F0Cg==">iBio, Inc</a>. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio's proprietary technology stack and was designed for subcutaneous administration with the potential for an extended half-life.
Pursuant to the agreement, AstralBio will receive an upfront payment of $750,000, which iBio has paid by issuing its common stock to AstralBio. In addition, AstralBio will be eligible for development and commercialization milestone payments totaling up to $28 million. If iBio sublicenses the licensed product, AstralBio will receive low to mid-single-digit sublicense fees on the proceeds of the sublicense fees. iBio is solely responsible for the research and development, manufacturing and commercialization activities of the licensed product.
In parallel, iBio initiated a bispecific antibody program targeting myostatin/activin A to treat obesity and cardiometabolic disorders, leveraging its proprietary Drug Discovery Platform as well as the technology of IBIO-600. The myostatin licensing agreement and planned myostatin/activin A bispecific antibody program follows a drug discovery and development collaboration between iBio and AstralBio initiated less than a year ago. iBio plans to enter into clinical investigation in obesity and cardiometabolic disorders in 2026.

iBio Expands Obesity Program with $750K Upfront Payment and $28M AstralBio Partnership

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) with a Buy rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

LUCID CAPITAL MARKETS Initiates Coverage On iBio with Buy Rating, Announces Price Target of $6

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.48) by 4.17 percent. This is a 89.15 percent increase over losses of $(4.24) per share from the same period last year.

Earnings Beats

iBio Q1 EPS $(0.46) Beats $(0.48) Estimate

iBio And AstralBio Say They 'have identified a molecule with therapeutic potential for treating muscle wasting and obesity, which is designed for subcutaneous administration and has potential for an extended half-life'; Are Working On Plans To Advance This Molecule Into Non-cGMP In Vivo Studies

<h3>Gainers</h3>
<ul>
<li>Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) shares moved upwards by 324.2% to $31.48 during Monday's regular session. The company's market cap stands at $2.5 billion. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 17.27% to $0.13. The market value of their outstanding shares is at $1.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 16.37% to $1.35. The company's market cap stands at $81.2 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock moved upwards by 15.82% to $3.22. The company's market cap stands at $159.3 million. </li>
<li>WORK Medical Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) stock moved upwards by 15.49% to $5.44. The company's market cap stands at $79.3 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) stock rose 14.84% to $2.52. The market value of their outstanding shares is at $21.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares declined by 45.0% to $2.54 during Monday's regular session. The market value of their outstanding shares is at $2.1 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares decreased by 26.03% to $8.64. The company's market cap stands at $10.7 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock declined by 24.25% to $5.75. The company's market cap stands at $2.9 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 19.0% to $0.52. The market value of their outstanding shares is at $2.5 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock declined by 15.84% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock decreased by 13.46% to $0.9. The market value of their outstanding shares is at $22.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

GLTO

LGMK

MHUA

SRRK

TCBP

TRVN

VIRI

VRPX

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock rose 198.1% to $22.12 during Monday's pre-market session. The company's market cap stands at $1.7 billion. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 53.16% to $0.17. The company's market cap stands at $2.0 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 15.21% to $0.31. The market value of their outstanding shares is at $2.2 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) stock moved upwards by 14.15% to $2.5. The market value of their outstanding shares is at $21.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 11.72% to $4.86. The market value of their outstanding shares is at $63.2 million. </li>
<li>Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) shares moved upwards by 10.58% to $52.67. The company's market cap stands at $5.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 45.5% to $2.51 during Monday's pre-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 18.3% to $0.49. The company's market cap stands at $1.5 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock declined by 14.69% to $4.01. The market value of their outstanding shares is at $2.9 million. </li>
<li>TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) shares decreased by 12.97% to $3.96. The company's market cap stands at $116.0 million. </li>
<li>SHL Telemedicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) shares fell 12.61% to $2.98. The market value of their outstanding shares is at $48.8 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock decreased by 12.51% to $0.35. The market value of their outstanding shares is at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BHVN

ENTO

NKGN

ONCO

SHLT

TLSI

12 Health Care Stocks Moving In Monday's Pre-Market Session

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) to report quarterly earnings at 82 cents per share on revenue of $645.50 million after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. AAR shares edged lower to $69.26 in after-hours trading.</li>
<li>ShiftPixy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) announced a 1-for-15 reverse stock split. ShiftPixy shares gained 0.8% to $1.21 in the after-hours trading session.</li>
<li>Analysts expect Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) to post a quarterly loss at 8 cents per share on revenue of $3.85 million after the closing bell. Red Cat shares gained 0.3% to $3.14 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>iBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) posted a consolidated net loss of $24.9 million for the fiscal year ended June 30, versus a year-ago loss of $65.01 million. Its revenue jumped 100% to around $0.2 million. iBio shares fell 0.5% to $1.96 in the after-hours trading session.  </li>
<li>Before the markets open, Uxin Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NYSE">UXIN</a>) is projected to report earnings results for the first quarter. Uxin shares fell 1.6% to $1.56 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(6.50) per share which beat the analyst consensus estimate of $(7.41) by 12.28 percent. The company reported quarterly sales of $225.000 thousand which beat the analyst consensus estimate of $25.000 thousand by 800.00 percent.

iBio FY 2024 GAAP EPS $(6.50) Beats $(7.41) Estimate, Sales $225.000K Beat $25.000K Estimate

Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) with a Buy rating and announces Price Target of $3.6.

Brookline Capital Initiates Coverage On iBio with Buy Rating, Announces Price Target of $3.6

<a href="https://patentcenter.uspto.gov/applications/17821295/ifw/docs" title="https://patentcenter.uspto.gov/applications/17821295/ifw/docs">https://patentcenter.uspto.gov/applications/17821295/ifw/docs</a>

iBio Receives Notice of Allowance for US Patent Application 17/821,295 Titled "Anti-CD-25 Antibody for the Treatment of Cancer"

Chardan Capital analyst Keay Nakae maintains iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) with a Buy and maintains $5 price target.

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

Chardan Capital analyst Keay Nakae initiates coverage on iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) with a Buy rating and announces Price Target of $5.

Chardan Capital Initiates Coverage On iBio with Buy Rating, Announces Price Target of $5

iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per share from the same period last year.

iBio Q3 EPS $(0.71) Up From $(9.53) YoY

Offerings

iBio Files Prospectus Relates To Resale From Time To Time Of Up To 10.6M Shares Of Common Stock By Selling Stockholders

<h3>Gainers</h3>
<ul>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 205.16% to $1.95. The market value of their outstanding shares is at $53.6 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares moved upwards by 78.11% to $1.53. The market value of their outstanding shares is at $6.5 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares moved upwards by 50.45% to $0.25. The company's market cap stands at $2.1 million. </li>
<li>iBio (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#AMEX">IBIO</a>) shares moved upwards by 27.98% to $4.3. The market value of their outstanding shares is at $14.9 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares rose 27.5% to $4.45. The company's market cap stands at $451.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 21.9% to $0.24 during Friday's pre-market session. The company's market cap stands at $12.6 million. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) stock fell 10.26% to $2.45. The company's market cap stands at $19.7 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 8.62% to $0.38. The market value of their outstanding shares is at $9.9 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares decreased by 8.3% to $0.34. The market value of their outstanding shares is at $4.1 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 8.21% to $20.02. The company's market cap stands at $511.1 million. </li>
<li>Nautilus Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAUT#NASDAQ">NAUT</a>) shares fell 7.59% to $2.56. The company's market cap stands at $320.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AVTX

BCDA

BDRX

LENZ

MESO

NAUT

NCNA

PAVM

YTEN

12 Health Care Stocks Moving In Friday's Pre-Market Session

iBio Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NYSE">IBIO</a>) shares are surging after the company entered into a collaboration agreement with&nbsp;AstralBio Inc.&nbsp;on Wednesday to discover, engineer, and develop antibodies to treat obesity and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37953815/ibio-and-astralbio-announce-transformative-ai-drug-discovery-collaboration-to-rapidly-develop-nove" rel="noreferrer noopener">other cardiometabolic conditions</a>.
The shares are trading over 100% with a strong session volume of 38.98 million compared to an average volume of average Volume 106.958K as per data from&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
This micro-cap biotech player is valued at $4 million, with an enterprise value of $17.7 million.
Tuesday, iBio&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=VWqAuWHsbf4qyXl8rzvujAopwBR5KiSlh_LLBysPX1mcmPMn4TfmtBNqWj6u5poldRH_UDrgaKyswkfYky-rXFNgCo2HyR_bvb2UGESTZt6zgajcgsj-rWKk5KQalNKB2lN2MoRkEzVaJjRgjA1x4Aw9myOuLhltEQZXfCG4R6loE8CRtDGNm5dGosBphtSGbVnv18XfCksYNmkjvTX62g==" rel="noreferrer noopener">announced</a>&nbsp;the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital, and other institutional investors.&nbsp;
The company will use some of the net proceeds to support new partnerships, such as this collaboration with AstralBio.
As part of the collaboration, iBio has granted an exclusive license to its AI-powered technology to identify and engineer four targets for cardiometabolic disease, of which AstralBio may continue the pre-clinical development and deploy its proven drug development expertise to advance candidates to an Investigational New Drug (IND) application.&nbsp;
iBio has the exclusive option to license three cardiometabolic targets from AstralBio and will receive the rights to develop, manufacture and commercialize those targets upon exercise.&nbsp;
As a result of this collaboration, iBio and AstralBio have agreed to initiate the development of a lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for the treatment of muscle wasting and obesity.&nbsp;
Upon mutual consent, the parties may expand the collaboration to include additional targets in other fields.
&#8220;We are confident our AI-enabled technology is exceptionally well positioned to develop antibodies against challenging targets in the cardiometabolic space,&#8221; said iBio&#8217;s CEO and Chief Scientific Officer, Martin Brenner.
Price Action: IBIO shares are up 147.80% at $2.84 on the last check Wednesday.
Photo via Shutterstock

Comments

iBio

iBio (IBIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga